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Abstract Since its ﬁrst description by Denis Burkitt, endemic Burkitt’s lymphoma (BL), the
most common childhood cancer in sub-Saharan Africa, has led scientists to search for clues to
the origins of this malignancy. The discovery of Epstein-Barr virus (EBV) in BL cells over 50 years
ago led to extensive sero-epidemiology studies and revealed that rather than being a virus
restricted to areas where BL is endemic, EBV is ubiquitous in the world’s population with an
estimated greater than 90% of adults worldwide infected. A second pathogen, Plasmodium fal-
ciparum (P. falciparum) malaria is also linked to BL. In this review, we will discuss recent studies
that indicate a role for P. falciparum malaria in dysregulating EBV infection, and increasing the
risk for BL in children living where P. falciparum malaria transmission is high.
© 2016 Published by Masson Doyma México S.A. on behalf of Hospital Infantil de Méx-
ico Federico Gómez. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Infección en lactantes por virus de Epstein-Barr: implicaciones de la infección
a temprana edad sobre el control viral y el riesgo de linfoma de Burkitt
Resumen Desde la primera descripción por Denis Burkitt, el linfoma de Burkitt (LB) endémicofalciparum;
Malaria;
Citidina desaminasa
inducida por
----el tipo de cáncer pediátrico más común en el África subsahariana---- ha guiado a los cientí-
ﬁcos a investigar este padecimiento en la búsqueda de claves para entender sus orígenes. El
descubrimiento desde hace 50 an˜os del virus de Epstein-Barr (VEB) en el LB ha conducido a
extensos estudios sero-epidemiológicos y ha revelado que, más que ser un virus restringido a
áreas donde el LB es endémico, el VEB es ubicuo en la población mundial, con un estimado
infectados a escala global. Un segundo agente patógeno se ha
activación
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ligado  al  LB,  el  Plasmodium  falciparum  (P.  falciparum)  malaria.  En  esta  revisión  se  discuten
los  estudios  recientes  que  indican  el  papel  de  P.  falciparum  malaria  en  la  desregulación  de  la
infección  por  VEB  y  en  el  aumento  del  riego  del  LB  en  nin˜os  que  viven  en  regiones  con  alta
transmisión  de  P.  falciparum  malaria.
©  2016  Publicado  por  Masson  Doyma  México  S.A.  en  nombre  de  Hospital  Infantil  de
México  Federico  Gómez.  Este  es  un  artículo  Open  Access  bajo  la  licencia  CC  BY-NC-ND
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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s. Introduction
urkitt’s  lymphoma  (BL)  is  a  monoclonal  B  cell  non-Hodgkin’s
ymphoma with  a  high  proliferative  index1.  Endemic  BL  is
xtranodal and  tumors  are  frequently  found  in  the  jaw
r abdominal  region2.  The  peak  age  of  onset  is  6  years3
ndicating  that  there  is  a  very  short  time  frame  between
xposure to  cancer  promoting  events  and  the  emergence  of
alignancy. There  are  three  forms  of  BL  found  worldwide:
ndemic, sporadic,  and  AIDS-associated  and  all  carry  a  t8;14
hromosomal translocation  resulting  in  the  deregulation  of
he c-myc  oncogene4,5.  It  is  likely  however,  that  different
athogenic mechanisms  drive  the  emergence  of  these  BL
ubtypes6,7.  The  focus  of  this  review  is  on  the  endemic  form
f BL  (herein  referred  to  simply  as  BL).
Both  molecular  and  epidemiologic  studies  have  indicated
hat there  is  an  etiologic  link  between  EBV  and  the  endemic
orm of  BL8--11.  At  the  molecular  level,  the  viral  genome  is
resent in  all  cells12,  exists  as  a  clonal  population  within
he tumors9 and  the  viral  protein  EBNA-113 along  with  viral
on-coding BART  microRNAs14,15 are  consistently  expressed
ithin the  tumors.  In  addition,  the  capacity  of  EBV  to  trans-
orm B  cells  also  highlights  the  virus’  oncogenic  potential.
 large-scale  prospective  study  conducted  in  Uganda  in  the
970s provided  evidence  that  EBV  infection  was  a  risk  factor
or BL.  In  this  study,  greater  than  40,000  children  were  pre-
led, serum  was  stored  and  when  tumors  appeared,  very
igh antibody  titers  against  the  EBV  viral  capsid  antigen
VCA) were  found  in  children  who  subsequently  developed
L. The  elevated  VCA  titers,  and  the  stability  of  the  ele-
ated VCA  antibodies  over  time,  led  de-Thé  et  al.16 to
uggest that  infection  of  infants  with  EBV  early  in  life  could
esult in  an  infection  that  was  poorly  controlled  by  the  host
nd thus  increased  the  risk  for  BL.  Plasmodium  falciparum,
s also  connected  to  BL  both  based  on  the  overlapping
egions of  high  malaria  transmission  with  areas  of  high  BL
ncidence17--20 as  well  as  case  control  studies21,22.
. Epstein-Barr virus transmission
BV  is  an  enveloped  gamma  herpes  virus  that  is  transmit-
ed primarily  through  contact  with  saliva23.  In  developed
ountries, there  is  a  biomodal  distribution  of  the  age  of  EBV
nfection with  30-50%  of  children  infected  before  5  years  of
ge and  then  a  later  transmission  occurring  in  young  adult-
ood. For  example,  in  a  recent  study  by  Condon  et  al.,  they
valuated the  seroprevalence  of  EBV  infection  in  a  cross-
ectional study  of  children  in  the  U.S.  aged  18  months-
0 years  of  age.  They  found  that  31%  of  the  children
ere EBV  seropositive  by  5  years  of  age,  whereas  71%  were
i
o
t
eeropositive  by  19  years  of  age24.  Infection  in  childhood  is
hought to  be  primarily  asymptomatic  while  the  later  age
f infection  can  cause  infectious  mononucleosis  (IM),  a  self-
imiting disease25.  IM  is  characterized  by  expansion  of  both
BV-speciﬁc and  non-speciﬁc  CD8+  T  cells.  In  a  study  of  Gam-
ian infants  infected  with  EBV  by  14  months  of  age,  although
here was  EBV-speciﬁc  CD8  T  cells  detected,  there  was  no
oncurrent over  expansion  of  the  CD8+  T  cell  pool26 perhaps
xplaining why  EBV  infection  in  infants  is  asymptomatic.
There  are  a  limited  number  of  published  longitudinal
tudies on  primary  EBV  infection  in  infants27--32 and  most
ave utilized  only  serologic  markers  as  indicators  of  infec-
ion. In  a  more  recent  study  following  an  infant  cohort
orn in  rural  areas  in  Kenya,  signiﬁcantly  higher  levels  of
BV infection  at  less  than  1  year  of  age  were  observed
s compared  to  other  studies31.  Of  note,  in  the  malaria
igh transmission  area,  35%  of  infants  were  infected  with
BV by  6  months  of  age  suggesting  that  malaria  infection
odulated the  age  of  EBV  infection31.  Early  age  of  EBV
nfection was  also  observed  in  Kenyan  infants  born  to  HIV
nfected mothers32.  Both  of  these  studies  found  that  early
ge of  acquisition  of  EBV  was  associated  with  a  poor  control
f EBV  infection  as  indicated  by  high  viral  loads  that  were
aintained over  time.  The  neonatal  immune  system  is  not
s  effective  as  the  adult  immune  system  for  reasons  that
nclude lack  of  immunologic  memory,  immaturity  and  ske-
ing towards  a  Th2  phenotype33--35.  Early  transmission  of  EBV
ould induce  tolerance  of  the  viral  antigen  and  consequently
imit the  speciﬁc  immune  response,  as  seen  for  early  age
f hepatitis  B  virus  infection36. Alternatively,  infants  lack  a
ully functional  cytotoxic  T  cell  response  before  12  months
f age34, so  infection  early  in  life  could  lead  to  ineffec-
ive or  minimal  control  of  the  virus.  Early  age  of  infection
ith subsequent  high  viral  loads  could  increase  the  risk  for
ubsequent EBV-associated  malignancies.
An  alternative  source  of  EBV  transmission  has  been
ypothesized to  be  breast  milk37--39 but  in  most  studies  to
ate, only  viral  DNA  was  measured.  More  recently,  infec-
ious virus,  not  just  viral  DNA,  was  found  in  breast  milk
roviding support  to  the  hypothesis  that  breast  milk  could
e a  source  for  EBV  transmission40. Pregnant  women  with
alaria have  high  viral  loads41,  and  the  loss  of  control  of
BV latency  following  P.  falciparum  infection  during  preg-
ancy and  subsequent  increase  in  EBV  load  in  circulation
ossibly contribute  to  enhanced  shedding  of  EBV  in  maternal
reast milk  post-partum40 and  drives  early  age  of  transmis-
ion of  EBV.  EBV  DNA  was  detected  in  breast  milk  of  HIV
nfected mothers38,39 and  this  could  contribute  to  early  age
f EBV  infection  in  infants  born  to  HIV  infected  women.  Why
here is  higher  prevalence  of  EBV  in  breast  milk  of  moth-
rs in  developing40 as  compared  to  developed  countries42
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could  also  reﬂect  the  higher  burden  of  EBV  in  the  general
population.
3. EBV persistence
A  model  for  EBV  persistence  proposed  by  Thorley-Lawson,
the Germinal  Center  (GC)  Model,  is  an  elegant  model  based
on years  of  study  of  healthy  U.S.  adults43.  In  this  model,
EBV exploits  the  differentiation  of  B  cells  in  the  lymphoid
tissue to  set  up  a  lifelong  persistent  latent  infection  in
memory B  cells  in  equilibrium  with  the  host.  In  healthy,
EBV-seropositive adults,  there  is  a  stable,  low  frequency  of
latently infected  cells  estimated  at  1-200  EBV  positive  B  cells
in 105 total  B  cells44.  Without  enrichment  for  B  cells  from
peripheral blood,  it  is  difﬁcult  to  detect  EBV  infected  cells
in healthy  EBV  seropositive  adults  by  PCR  ampliﬁcation  using
real-time  quantitative  PCR45,46 or  quantitative  competitive
PCR47.  However,  unaccounted  for  in  this  model  is  how  other
systemic infections  can  inﬂuence  EBV  persistence.
3.1.  Malaria  and  EBV  persistence
In  the  last  decade,  several  studies  have  pointed  to  a  pro-
found dysregulation  of  EBV  persistence  and  immunity  in
children due  to  malaria31,46,48--57.  Repeated  malaria  infec-
tions during  infancy  expand  the  viral  load54 and  an  expansion
of EBV  infected  cells  during  acute  malaria  has  also  been
found49,58.  The  cysteine  rich  interdomain  1  (CIDR1)  of
the P.  falciparum  erythrocyte  membrane  protein,  which  is
expressed in  infected  red  blood  cells,  binds  to  non-immune
immunoglobulins, and  acts  as  a  T-cell  independent  B-cell
activator59 and  induces  EBV  reactivation  from  B  cells60. EBV
is more  frequently  reactivated  in  children  living  in  a  malaria
endemic region48 and  more  directly,  elevated  viral  DNA  in
plasma is  found  during  acute  malaria51,52.  A  decline  in  EBV
DNA in  the  plasma  following  anti-malaria  treatment53 is  also
indicative of  viral  reactivation  driven  by  Plasmodium  infec-
tion.
In children  living  in  a  malaria  endemic  region,  EBV  viral
loads are  more  readily  detected  as  compared  to  west-
ern controls46,49 suggestive  of  a  long-term  consequence  of
repeated malaria  infections.  More  recently,  in  regions  of
the Gambia  where  malaria  transmission  has  been  reduced,
the dysregulation  of  EBV  immunity  by  malaria  appears  to
have also  been  minimized61.
4. Activation induced cytidine deaminase
(AID)  and BL
While  it  is  likely  that  elevated  EBV  load  increases  the  risk  for
BL, the  mechanistic  link  is  unknown.  In  transplant  patients,
EBV viral  load  is  monitored  closely  and  elevated  viral  load  is
associated with  increased  risk  for  post-transplant  lympho-
proliferative disease62 yet  these  patients  do  not  go  on  to
develop BL.  So,  elevated  viral  load  alone  is  not  sufﬁcient  for
the emergence  of  a  malignant  clone.  Recent  clues  point  to
a model  where  chronic  antigenic  activation  of  EBV-infected
B cells  within  the  context  of  repeated  P.  falciparum  infec-
tions may  lead  to  cytogenetic  abnormalities  induced  by  the
enzyme activation  induced  cytidine  deaminase  (AID)63--65.
o
c
s
i43
AID  is  required  for  class  switch  recombination  and
omatic hypermutation  in  germinal  center  B  cells66.  But
ID over-expression  in  AID  deﬁcient  B  cells  was  sufﬁcient
o induce  IgH-c-myc  translocations67 characteristic  of  BL.
ID also  induces  lesions  on  the  c-myc  gene68.  In  addi-
ion, when  E-c-myc  transgenic  mice  were  crossed  with
ID deﬁcient  mice,  only  AID+/+  mice  developed  predomi-
antly mature  B  cell  lymphomas69.  The  strongest  evidence
or a  role  of  aberrant  AID  activation  by  Plasmodium  infec-
ion comes  from  a  recent  study  by  Robbiani  et  al.70 In
his study,  the  authors  found  that  repeated  infections  of
53-deﬁcient mice  with  Plasmodium  chabaudi  resulted  in
evelopment of  B-cell  lymphomas  that  had  the  character-
stic c-myc  translocation.  Moreover,  development  of  the
ymphomas was  dependent  on  AID.  Although  these  studies
ere done  in  mouse  models,  these  data  argue  for  a critical
ole of  AID  in  the  c-myc:IgH  translocation  characteristic  of
L and  suggest  that  aberrant  AID  expression  could  be  a  risk
actor for  lymphomagenesis.  In  support  of  this  hypothesis,
 strong  correlation  between  AID  expression  in  peripheral
lood lymphocytes  and  increased  risk  for  non-Hodgkin’s  lym-
homa was  observed71,72 and  children  who  were  EBV  viral
oad positive  from  a  malaria  endemic  region  were  found  to
ave elevated  AID  expression63. Cell  culture  studies  showed
hat P.  falciparum  could  induce  AID  activation  and  class
witch recombination  in  B  cells64,73.  If  overexpression  of
-myc occurred  following  an  AID-mediated  translocation,
ormal B  cells  would  die  by  apoptosis.  However,  EBV  latent
roteins are  anti-apoptotic  and  could  thus  allow  a  B  cell  to
olerate the  c-myc  translocation74.
.  BL and EBV association
lthough  EBV  can  be  readily  detected  in  the  endemic  pedi-
tric form  of  BL  found  in  sub-Saharan  Africa,  there  is  a
ariable association  of  EBV  with  the  sporadic  form  of  BL.
poradic BL  that  occurs  in  adults  in  developed  countries
arely has  EBV  detected  in  the  tumor.  However,  in  South
merica, there  is  an  intermediate  level  of  EBV  detected
n sporadic  BL  tumors75. A  larger  series  of  cases  of  BL
rom Brazil  found  a predominance  of  EBV  detection  in  the
ediatric form  of  BL  as  compared  to  adults  and  a  higher
revalence of  pediatric  EBV+  BL  in  the  northern  part  of
razil where  there  is  also  a  higher  prevalence  of  malaria  and
ther infectious  diseases76.  The  intermediate  incidence  of
BV association  with  sporadic  BL  in  South  America  raises  the
uestion of  whether  malaria  infection  in  other  parts  of  the
orld outside  sub-Saharan  Africa  could  also  drive  lymphoma-
enesis. A  key  difference  of  malaria  transmission  in  Africa
s the  perennial  and  intense  nature  vs.  the  epidemic  and
easonal transmission  found  in  South  and  Central  America.
owever, it  is  possible  that  there  could  exist  a  concurrence
f early  age  of  EBV  infection  and  malaria  infection  that
ould increase  the  risk  for  lymphomagenesis  in  other  parts
f the  world.  Studies  on  the  age  of  EBV  infection  in  Latin
merica remain  few.  A  recent  report  from  a  pediatric  hos-
ital case  series  in  Mexico  found  symptomatic  EBV  infection
ccurring in  children  characteristic  of  infectious  mononu-
leosis with  a  mean  age  of  5  years,77 much  younger  than
een in  U.S.-based  series23. However,  a  limitation  of  the  Mex-
co study  is  that  it  was  based  on  hospitalized  cases  rather
44  R.  Rochford
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Figure  1  Model  for  interaction  between  EBV  and  P.  falciparum  malaria.  P.  falciparum  (Pf)  malaria  results  in  EBV  transmission
in infants  <6  months  of  age.  These  infants  have  poor  control  of  EBV  infection  and  a  higher  number  of  latently  infected  cells.
Repeated  infection  with  P.  falciparum  throughout  infancy  and  early  childhood  expands  the  number  of  infected  cells  by  inducing  EBV
reactivation  and  reinfection  of  new  pool  of  B  cells  as  well  as  suppression  of  EBV  T  cell  immunity.  P.  falciparum  can  also  act  on  the
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RBV  infected  B  cells  to  induce  AID  via  TLR9  ligation  and  subseq
n  the  infected  B  cells,  the  c-myc  translocation  is  tolerated  and
han  a  population-based  study  so  true  incidence  cannot  be
etermined. Nonetheless,  this  study  does  suggest  that  EBV
nfection is  occurring  in  very  young  children  in  Mexico.
ummary
umulative  evidence  suggests  that  EBV  persistence  is  in
ysequilibrium when  primary  infection  occurs  in  very  young
nfants and  co-infection  with  P.  falciparum  malaria  is
ommon. The  prevailing  model  for  EBV  persistence,  the
erminal center  model,  was  based  on  studies  of  healthy
.S. adults  and  as  such  does  not  take  into  account  the
isruption to  B cell  homeostasis78,79 and  germinal  center
rchitecture that  occurs  during  acute  P.  falciparum  malaria
nfection80 or  the  ability  of  Plasmodium  to  directly  inter-
ct with  B  cells  through  either  TLR9  ligation81 or  binding  of
he P.  falciparum-infected  red  blood  cell  to  B  cells60. This
ysequilibrium of  EBV  persistence  results  in  high  numbers  of
atently infected  cells,  which  are  at  risk  for  AID  activation
nduced by  P.  falciparum  and  subsequent  c-myc  transloca-
ion (Fig.  1).  Not  discussed  in  this  review  is  a  potential  role
or EBV  to  suppress  apoptotic  pathways  in  latently  infected
ells,82 which  would  allow  B  cells  with  a  c-myc  translocation
o emerge.  It  remains  to  be  seen  whether  other  pathogens
an also  lead  to  dysequilibrium  of  EBV  infection  and  higher
iral loads  and  account  for  some  of  the  diverse  burden  of
BV-associated malignancies  worldwide.onﬂict of interest
he  author  declares  no  conﬂict  of  interest  of  any  nature.
1 c-myc  translocation.  Because  EBV  induces  epigenetic  changes
re  is  emergence  of  a  malignant  B  cells.
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